In this setting, PTPN11 inhibition induced a shift in tumour microenvironment (TME) myeloid cell populations towards an inflammatory, anti-tumour phenotype, in part via effects on colony-stimulating factor 1 (CSF1) signalling pathways [52]. The gene discussed is PTPN11; the disease is neoplasm.